medigraphic.com

2019, Number 1

<< Back Next >>

Cuba y Salud 2019; 14 (1)

Microbiological surveillance of bacterial resistant in methicillin resistant Staphylococcus spp. General Calixto García Universitary Hospital. 2015-2017

Madruga FMC, Cepero BMC

Language: Spanish
References: 37
Page: 33-40
PDF size: 1167.99 Kb.


ABSTRACT

Objective: evaluate the isolates frecuency of Staphylococcus meticillin resistent like causal agent of infections, identify type of sample with hight percent of isolation, determine the antimicrobial susceptibility “in vitro” of methicillin resistant Staphylococcus spp and promove the training in prevention and control of infections associated to the health assistance.
Method: descriptive study made in the General Calixto García Universitary Hospital during the period 2015 to 2017. 2 049 clinical samples were analysed in admitted patients with Staphylococcus spp isolates. The bacterial isolates were identified via conventional methods of the Microbiology Laboratory. The antimicrobial susceptibility in vitro was determined by the Bauer-Kirby’s method and E-test methods for the vancomycin. The resistant mechanism to the meticillin was detected with cefoxitin (30 µg). The results interpretation was made according to the CLSI 2015’ standard.
Results: the incidence of methicillin resistant Staphylococcus isolations was 72,6%. The grave patients’ care Units were the services that had the major isolating; the most representative samples were the endotracheal aspirates and blood culture. There was a high percent of resistant to the majority of antimicrobial non betalactams proved. Tetracycline and chloramphenicol had the less resistant percent. There was no resistance to vancomycin.
Conclusions: the resistance to methicillin in Staphylococcus aureus was higher than negative coagulase staphylococcus with high percent resistant to the majority of antimicrobial non betalactams proved. Tetracycline, chloramphenicol and glycopedtides are option therapeutic.


REFERENCES

  1. Jevons MP. Celbenin-resistant Staphylococci. Br Med J 1961; 1: 124-125.

  2. Hiramatsu K, Hanki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin resistant Staphylococcus aureus clinical isolates with reduced vancomycin susceptibility. J Antimicrobial Chemotherapy 1997; 40: 135-136.

  3. Centers for Disease Control and Prevention. Sievert DM, Boulton ML, Stolman G, Johnson D, Stobierski M.G, Downer FP et al. Staphylococcus aureus resistant to vancomycin. United States, 2002. MMWR 2002; 51: 565-567.

  4. McClure JA, Zhang K. Complete genome sequence of a community-associated methicillin-resistant Staphylococcus aureus hyper virulent strain, USA300-C2406, isolated from a patient with a lethal case of necrotizing pneumonia. Genome Announce. 2017; 5 (22):1-3.

  5. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). 2009. Classification of staphylococcal cassette chromosome mec(SCCmec): guidelines for reporting novel SCCmec elements. Antimicrobial Agents Chemotherapy. 53:4961–4967.

  6. SS Tang, A Apisarnthanarak, L Yang Hsu. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and health care-associated multidrug resistant..., Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/10.1016/j.addr.2014.08.003.

  7. Bowen AC, Carapetis JR, Currie BJ, Fowler V, Chambers HF, Tong SYC. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for skin and soft tissue infections including impetigo, cellulitis, and abscess. Open Forum Infect Dis. 2017 fall; 4 (4): ofx232.

  8. A. C. Fluit. Livestock-associated Staphylococcus aureus Clin Microbial Infect 2012; 18: 735–744.

  9. Shallcross LJ, Fragaszy E, Johnson A M, Hayward A C. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and metaanalysis. Lancet Infectious Diseases, 2013-01-01, Volume 13, Issue 1, Pages 43-54.

  10. Rodvold Keith A, McConeghy Kevin W. Methicillin-Resistant Staphylococcus aureus. Therapy: Past, Present, and Future. Clinical Infectious Diseases 2014; 58(S1):S20–7.

  11. Global Action Plan on Antimicrobial Resistance, 2015 (http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_20-en.pdf?ua=1).

  12. Organización Mundial de la Salud. Worldwide country situation analysis: response to antimicrobial resistance. Geneva: World Health Organization, 2015 [citado 5 de Septiembre de 2017]. Disponible en: http://www.who.int

  13. Quiñones Pérez D. Resistencia antimicrobiana: evolución y perspectivas actuales ante el enfoque “Una salud” Revista Cubana de Medicina Tropical, Vol 69, No 3 (2017).

  14. Tacconelli E, Magrini N. Mundial priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 2017. p. 1-7.

  15. Organización Mundial de la Salud. Sistema Mundial de Vigilancia de la Resistencia a los Antimicrobianos: Manual para la primera fase de implementación. Ginebra: Organización Mundial de la Salud; 2017.

  16. Koneman E, Allen S. Koneman diagnóstico microbiológico: texto y atlas en color. 6ta Edic. Buenos Aires. Ed. Médica Pana¬mericana. p: 1696. 2008.

  17. Llop Hernández A, Valdés-Dapena Vivanco MM, Zuazo Silva JL. Microbiología y Parasitología médica. Tomo III; Cap 151. La Habana 2001; Pp. 609-618.

  18. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

  19. Morosini MI, Cercenado E, Ardanuy C, Torres C. Detección fenotípica de mecanismos de resistencia en microorganismos grampositivos. Enferm Infecc Microbiol Clin. 2012; 30 (6):325-32.

  20. Joseph Omololu AS. Staphylococcus aureus surface colonization of medical equipment and environment, implication in hospitalcommunity epidemiology. J Hosp Med Manage. 2017, 3:1.

  21. Boskey E. What is Fomite Transmission? Updated 2011 Accessed. 2013.

  22. Mangicaro S. Fomites: a vector for infection transmission. 2012 Updated 2012 cited 2013.

  23. Casellas JM. Resistencia a los antibacterianos en América Latina: consecuencias para la infectología. Rev Panam Salud Pública. 2011; 30(6): 519–28.

  24. Nodarse Hernández R: Detección de Staphylococcus aureus resistente a meticillina mediante disco de cefoxitina. Revista Cubana de Medicina Militar. 2009; 38(3-4):30-9.

  25. Hopman J, Toraño G et al. USA300 Methicillin-resistant Staphylococcus aureus in Cuba. Antimicrobial Resistance and Infection Control 2012, 1:2.

  26. Toraño G, Monzote A. Meticillin-resistant S. aureus in Cuba. The APUA-Newsletter. 2013; 3 (3):20-1.

  27. Espinosa Rivera F, Hart Casares M, Halley Posada MC, Martínez Batista ML, Pardo Nuñez A. Resistencia bacteriana de cepas aisladas en el Hospital “Hermanos Ameijeiras” Rev cubana med v.47 n.4 Ciudad de la Habana oct.-dic. 2008.

  28. Mederos Hernández J, Morejón García M. Frecuencia de aislamiento de Staphylococcus aureus resistente a meticillina en el Hospital “Manuel Fajardo Rivero “Rev Haban Cienc Méd vol.13 no.3 Ciudad de La Habana mayo-jun. 2014.

  29. Martínez-Oquendo A, Montes-de-Oca-Rivero M, Alemañy-Co J, Marrero-Silva I, Reyna Reyes R, Cedeño-Morales R. Resistencia antimicrobiana del Staphylococcus aureus resistente a meticilina en el Hospital Dr. Gustavo Aldereguía Lima. Medisur [revista en Internet] 2017 [citado 2017 May 23]; 15(2): [aprox. 6 p.] Disponible en:http://www.medisur.sld.cu/index.php/medisur/article/view/3321.

  30. Aties López Leonor, Moya Jústiz Gilberto, Milá Pascual Milagros de la Caridad, Figueredo Acosta Ileana del Carmen, Brossard Alejo Gardenia. Staphylococcus aureus y estafilococo coagulasa negativa resistentes a la meticilina. MEDISAN [Internet] 2017 Dic [citado 2018 Oct 17]; 21(12): 3300-3305. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192017001200003&lng=es.

  31. Infectious Diseases Society of America. IDSA Announces First Guidelines for Treatment of Methicillin Resistant Staphylococcus aureus (MRSA) Infections [Internet]. Arlington: IDSA; 2011. [cited 10 Ene 2016] Available from: http://www.idsociety.org/IDSA_Guidelines_for_ Treatment_of_MRSA_Infections/.

  32. E. Rodríguez-Noriega et al. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America/ International Journal of Infectious Diseases 14 (2010) 560–566.

  33. Duquesne Alderete, Castro Sánchez, Monzote López, Paredes Cuervo. Caracterización microbiológica de aislamientos de Staphylococcus aureus en muestras purulentas. Hospital Ortopédico “Fructuoso Rodríguez”. Enero-Mayo, 2014. Panorama Cuba y Salud 2015; 10 (2):17- 22.

  34. Monzote López, Toraño Peraza, Díaz Novo, Valdés-Dapena Vivanco. Incremento de las infecciones por Staphylococcus aureus resistente a la meticilina en un hospital pediátrico de Cuba. Panorama Cuba y Salud 2016;11 (1): 9-15.

  35. Holden MTG, Hsu L, Kurt K, Weinert LA, Mather AE, Harris SR, et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 2013; 23:653–64.

  36. World Health Organization. Vigilancia del uso de los antimicrobianos. Geneva: World Health Organization, 2017 [citado 5 de Septiembre de 2017]. Disponible en: http://www.who.int

  37. Fan R, Li D, Wang Y, He T, Febler AT, Schwarz S. Presence of the optrA Gene in Methicillin-Resistant Staphylococcus sciuri of Porcine Origin. Antimicrob Agents Chemother. 2016; 60(12):7200-5.




2020     |     www.medigraphic.com